You searched for Oncologie - Page 62 of 64

- 05 Décembre 2018

Exelixis and Ipsen initiate phase 3 pivotal trial (COSMIC-312) of cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma

...

- 25 Février 2019

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Attachment...

- 14 Février 2019

Ipsen delivers strong 2018 results and expects continued sales and profit growth in 2019

Paris (France), 14 February 2019 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its financial results for the full year 2018....

- 15 Novembre 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib

...

- 15 Novembre 2018

Ipsen obtient l’approbation européenne pour Cabometyx® (cabozantinib) pour le traitement du carcinome hépatocellulaire chez les adultes antérieurement traités par sorafénib

...

- 16 Janvier 2018

Ipsen annonce 13 posters et 1 présentation orale lors du Symposium sur les Cancers Gastro-intestinaux de l’ASCO

...

- 21 Septembre 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

...

- 29 Mai 2018

Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership

...

- 26 Juillet 2018

Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% and upgrades its guidance for full year 2018